AUSTIN, Texas, April  30, 2026  (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. (&#34;Rein&#34; or the &#34;Company&#34;) (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class

RNTX

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics Raises $50 Million in Public Offering for Clinical Trials

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>AUSTIN, Texas, April  30, 2026  (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. (&amp;#34;Rein&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Rein Therapeutics has priced its public offering at $1.00 per share, raising $50 million to fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis. This financial maneuver aims to bolster operational sustainability through 2028, potentially stabilizing investor confidence in the company&#039;s future prospects.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Rein Therapeutics prices public offering at $1.00 per share.</li><li>The company will raise $50 million for clinical trials and operational costs.</li><li>Offering includes 50 million shares, with a 45-day option for 7.5 million additional shares.</li><li>Proceeds expected to fund operations into 2028, providing financial stability.</li><li>LTI-03 is Rein&#039;s primary product for idiopathic pulmonary fibrosis.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Konik Capital Partners, LLC (N/A)</strong>: Acting as the book-running manager, supporting RNTX in equity markets.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This article fits under &#039;Corporate Developments,&#039; as it highlights a significant financing event essential for Rein Therapeutics&#039; clinical advancement and operational stability. The offering may signal to investors that the company is proactively addressing funding needs amidst ongoing trials.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The successful closure of the offering may reinforce RNTX&#039;s financial position.</li><li>Lti-03&#039;s trial progress could significantly impact future valuation metrics.</li><li>Market reaction may fluctuate based on investor sentiment toward the capital raise.</li><li>Widespread interest in orphan drugs may elevate RNTX&#039;s stock visibility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering priced at $1.00 per share for 50 million shares, totaling $50 million.</li><li>Underwriters have an option for an additional 7.5 million shares.</li><li>Proceeds will support ongoing LTI-03 Phase 2 trial and operational costs.</li><li>Offering expected to close around May 4, 2026.</li><li>Current plans suggest operational funding into 2028.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should cautiously consider buying RNTX due to funding support into 2028.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">AUSTIN, Texas, April  30, 2026  (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. (&#34;Rein&#34; or the &#34;Company&#34;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RNTX">RNTX</a>), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions. The offering consisted entirely of common stock with no warrants.</p>  <p align="justify"><strong>Konik Capital Partners, LLC, a division of T.R. Winston &amp; Company, LLC, is acting as the sole book-running manager for the offering.</strong></p>  <p align="justify">Rein intends to use the net proceeds from the offering to fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) through completion and for working capital and general corporate purposes. Based on its current operating plan, the Company believes the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operations into 2028.</p>  <p align="justify">The securities described above are being offered and sold pursuant to a registration statement on Form S-1 (File No. 333-295390), including a prospectus, filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), which was declared effective by the SEC on April 30, 2026. The offering is being made only by means of a prospectus that forms part of the effective registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=91O_eE-0IPDp3psoyIVJ1xoJCC1UvKXhhYAoGp5vjDdk_gwEG9-Ct7BlaAp5U7mfJDE6ca4fQsdpdxTD7hePRg==" rel="nofollow" target="_blank">http://www.sec.gov</a>. Copies of the final prospectus may be obtained, when available, from Konik Capital Partners, LLC, a division of T.R. Winston &amp; Company, LLC, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: <a href="mailto:capmarkets@konikcapitalpartners.com">capmarkets@konikcapitalpartners.com</a>.</p>  <p align="justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p><strong>About Rein Therapeutics</strong></p>  <p align="justify">Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.</p>  <p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company's LTI-03 and LTI-01 product candidates and the closing of the offering. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: (i) the risk that the offering may not be completed, (ii) the risk that the net proceeds of the offering may not be sufficient to fund the Company's operations into 2028, and (iii) those other risks disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026, and in subsequent filings that the Company makes with the SEC. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>  <p><strong>Rein Therapeutics Investor Relations &amp; Media Contact:</strong></p>  <p>Investor Relations</p>  <p><a href="https://www.globenewswire.com/Tracker?data=PjKWPzTr1h8hJwQ73wqvFlXQ2MQjQXDVTMnFKRK8P6xg1VWHnhg5SpmJ7O6c4XdIVtdO_9-PpyVdptHS7heZQw==" rel="nofollow" target="_blank"><strong>IR@ReinTx.com</strong></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTE1NyM3NTc3Njc5IzIwMTg0MDg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODhjNjY5NTEtZGNhYy00ZGM2LWIxNGMtNjJmMGQwOTY5Yzg3LTEwMjk5NzgtMjAyNi0wNS0wMS1lbg==/tiny/Rein-Therapeutics.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7012d0d8-d19b-4f82-be65-c10f3701019b"><img src="https://ml.globenewswire.com/media/7012d0d8-d19b-4f82-be65-c10f3701019b/small/logo-jpg.jpg" border="0" width="150" height="94" alt="Primary Logo"></img></a></p>

Rein Therapeutics has priced its public offering at $1.00 per share, raising $50 million to fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis. This financial maneuver aims to bolster operational sustainability through 2028, potentially stabilizing investor confidence in the company's future prospects.

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News